Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 10:17 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–43 of 43 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Telmisartan 40mg Clear all

Conditions: Hypertension
Interventions: amlodipine, telmisartan, telmisartan and amlodipine; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 858 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 30
States / cities: Buena Park, California • Long Beach, California • Roseville, California + 26 more

Conditions: Atrial Fibrillation
Interventions: Dabigatran etexilate, Warfarin; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 140,187 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Respiratory Tract Diseases, Influenza (Pandemic), Influenza, Community Acquired Pneumonia, Community Acquired Pneumonia (CAP), Community Acquired Pneumonia, Severe, COVID-19, Respiratory Tract Infection Acute, Respiratory Tract Infections (RTI), SARS CoV 2 Infection
Interventions: Ceftriaxone + Macrolide, Moxifloxacin or Levofloxacin, Piperacillin-tazobactam + Macrolide, Ceftaroline + Macrolide, Amoxicillin-clavulanate + Macrolide, Standard course macrolide, Extended course macrolide, No systemic corticosteroid, Fixed-duration Hydrocortisone, Shock-dependent hydrocortisone, Fixed-duration higher dose Hydrocortisone, No antiviral agent for influenza, Five-days oseltamivir, Ten-days oseltamivir, No antiviral agent for COVID-19, Lopinavir / Ritonavir, Hydroxychloroquine, Hydroxychloroquine + lopinavir/ritonavir, Ivermectin, No immune modulation for COVID-19, Interferon beta-1a, Anakinra, Tocilizumab, Sarilumab, Local standard venous thromboprophylaxis, Therapeutic dose anticoagulation, Conventional low dose thromboprophylaxis, Intermediate dose thromboprophylaxis, Continuation of therapeutic dose anticoagulation, No immunoglobulin, Convalescent plasma, Delayed administration of convalescent plasma, No vitamin C, Vitamin C, No antiplatelet, Aspirin, P2Y12 inhibitor, No simvastatin, Simvastatin, Eritoran, Apremilast, Clinician-preferred mechanical ventilation strategy, Protocolised mechanical ventilation strategy, No renin-angiotensin system inhibitor, Angiotensin converting enzyme inhibitor, Angiotensin Receptor Blockers, ARB + DMX-200, No cysteamine, Cysteamine, Fixed-duration dexamethasone, Baloxavir Marboxil, Five-days oseltamivir + baloxavir marboxil, Ten-days oseltamivir + baloxavir marboxil, No endothelial modulator, Imatinib, No Immune Modulator for Influenza, Baricitinib, Nirmatrelvir/ritonavir, Remdesivir, Nirmatrelvir/ritonavir + remdesivir, Amoxicillin-clavulanate + Ceftazidime + Macrolide, Meropenem + Macrolide; Drug · Other · Biological + 1 more
Lead sponsor: UMC Utrecht; Other
Eligibility: 28 Days and older
Enrollment: 20,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2029
U.S. locations: 11
States / cities: Jacksonville, Florida • Augusta, Georgia • Chicago, Illinois + 8 more

Conditions: Stroke
Interventions: Aggrenox, Clopidogrel placebo, Micardis, Aggrenox placebo, Clopidogrel, Micardis placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 50 Years and older
Enrollment: 20,332 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 204
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 160 more

Conditions: Hypertension
Interventions: telmisartan 80 mg / hydrochlorothiazide 25 mg, valsartan 160 mg / hydrochlorothiazide 25 mg, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,185 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2006
U.S. locations: 113
States / cities: Athens, Alabama • Birmingham, Alabama • Huntsville, Alabama + 90 more

Conditions: Hypertension, Diabetic Nephropathies
Interventions: telmisartan, losartan; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 21 Years to 80 Years
Enrollment: 860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 47
States / cities: Montgomery, Alabama • Little Rock, Arkansas • Lancaster, California + 41 more

Conditions: Peripheral Artery Disease
Interventions: Supervised Treadmill Exercise Therapy, Telmisartan, "No exercise" control group, Placebo; Behavioral · Drug · Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2022
U.S. locations: 3
States / cities: Chicago, Illinois • New Orleans, Louisiana

Conditions: Cardiovascular Diseases
Interventions: Telmisartan, Combination of Telmisartan and Ramipril, Ramipril; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 55 Years and older
Enrollment: 31,546 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2001
U.S. locations: 100
States / cities: Athens, Alabama • Birmingham, Alabama • Phoenix, Arizona + 84 more

Conditions: Hypertension, COVID
Interventions: ACEI/ARB, Non-ACEI/ARB, ACEI, ARB; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22,213 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: HIV Infection
Interventions: Telmisartan; Drug
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Enrollment: 35 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Hypertension
Interventions: telmisartan 80 mg/hydrochlorothiazide 25 mg, valsartan 160 mg/hydrochlorothiazide 25 mg, placebo; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 1,109 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2003
U.S. locations: 100
States / cities: Birmingham, Alabama • Huntsville, Alabama • Mobile, Alabama + 90 more

Conditions: Hypertension
Interventions: Telmisartan, Hydrochlorothiazide; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 894 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2009
U.S. locations: 18
States / cities: Athens, Alabama • Mobile, Alabama • Lomita, California + 14 more

Conditions: GVHD
Interventions: Telmisartan; Drug
Lead sponsor: Hackensack Meridian Health; Other
Eligibility: 18 Years to 99 Years
Enrollment: 32 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2023
U.S. locations: 1
States / cities: Hackensack, New Jersey

Conditions: Hypertension
Interventions: Ramipril, Telmisartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 63,744 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Kidney, Polycystic
Interventions: Lisinopril, Telmisartan, Placebo; Drug
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: 15 Years to 64 Years
Enrollment: 486 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2014
U.S. locations: 7
States / cities: Aurora, Colorado • Atlanta, Georgia • Kansas City, Kansas + 3 more

Conditions: Chronic Kidney Disease, Type 2 Diabetes
Interventions: Finerenone, Semaglutide, Lotensin, Capoten, Enalapril, Monopril, Lisinopril, Univasc, Aceon, Accupril, Altace, Mavik, Edarbi, Atacand, Avapro, Cozaar, Benicar, Micardis, Diovan, Invokana, Farxiga, Jardiance, Ertugliflozin, Brenzavvy, Sotagliflozin; Drug
Lead sponsor: Baylor Research Institute; Other
Eligibility: 18 Years to 84 Years
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Temple, Texas

Conditions: COVID-19
Interventions: Telmisartan 40mg, Placebo; Drug
Lead sponsor: University of Hawaii; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2022
U.S. locations: 1
States / cities: Honolulu, Hawaii

Conditions: Hypertension
Interventions: Telmisartan & Hydrochlorothiazide, Losartan & Hydrochlorothiazide, ABPM; Drug · Procedure
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 18 Years and older
Enrollment: 805 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2002
U.S. locations: 69
States / cities: Huntsville, Alabama • Little Rock, Arkansas • Carmichael, California + 57 more

Conditions: Hypertension
Interventions: Loop diuretics, thiazides, dihydropyridines, Telmisartan; Drug
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 55 Years and older
Enrollment: 40,048 participants
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Boston, Massachusetts

Search by objective public record fields.

Telmisartan and Amlodipine Fixed Dose Combination [FDC] Trial for the Treatment of Severe Hypertension

Validation of Predictors of OAC Initiation Using EMR Data

Randomized, Embedded, Multifactorial Adaptive Platform Trial for Community- Acquired Pneumonia

PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes

Randomized, Double-Blind, Placebo-Controlled, Forced-Titration, Comparing Telmisartan vs Valsartan. Taken Orally for Eight Weeks in Patients With Stage 1 and Stage 2 Hypertension

A Prospective, Randomised, Double-blind, Double-dummy, Forced-titration, Multicentre, Parallel Group, One Year Treatment Trial to Compare Telmisartan (MICARDIS) 80 mg Versus Losartan (COZAAR) 100 mg, in Hypertensive Type 2 Diabetic Patients With Overt Nephropathy (AMADEO Study)

Telmisartan Plus Exercise to Improve Functioning in Peripheral Artery Disease

Effectiveness and Safety of Ramipril Alone Compared With Telmisartan Alone and in Combination With Ramipril in Patients at High Risk for Cardiovascular Events. Patients Intolerant to Ramipril Were Entered in TRANSCEND, Telmisartan Compared to Placebo.

ACEI or ARB and COVID-19 Severity and Mortality in US Veterans

HIV and Fat Accumulation

A Randomized, Double-blind, Placebo Controlled Comparison of Telmisartan Hydrochlorothiazide (HCT) and Valsartan HCT in Hypertension (HTN) Stage I/II Patients

Telmisartan 80mg Plus Hydrochlorothiazide 25mg First Line in Moderate or Severe Hypertension

Study of TelmisartanFor the Prevention of Acute GVHD Post Allogeneic Hematopoietic Stem Cell Transplantation

Replication of the ONTARGET Antihypertensive Trial in Healthcare Claims Data

HALT Progression of Polycystic Kidney Disease Study B

Rapid and Simultaneous Initiation of Four Guideline-Directed CKD Therapies (RAPID-CKD)

Pilot Clinical Trial of the Safety and Efficacy of Telmisartan for the Mitigation of Pulmonary and Cardiac Complications in COVID-19 Patients

PROBE Parallel 6-week Treatment Comparing Telmisartan/Hydrochlorothiazide (HCT) (40/12.5 or 80/12.5) With Losartan/HCT (50/12.5) Using Ambulatory Blood Pressure Monitoring (ABPM)

Replication of the TRANSCEND Antihypertensive Trial in Healthcare Claims Data